At Mycovia, we are passionate about developing breakthrough therapies in women’s health and dermatology.
Mycovia Pharmaceuticals was formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. At Mycovia, we are passionate about developing breakthrough therapies in women’s health and dermatology. Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a yeast infection that affects millions of women each year and often leads to distressing physical discomfort and a negative impact on psychological well-being. In studies to date, VT-1161 has demonstrated a high degree of potency against the organisms that cause RVVC. It may also have a lesser tendency to induce drug resistance and the variety of side effects that limit the use of currently available oral antifungal therapies. We are conducting global Phase 3 clinical trials in RVVC.
VT-1161 has also been studied in onychomycosis, a fungal infection of the nail which affects approximately 35 million people in the United States and millions more around the globe. Onychomycosis can be a significant medical issue particularly for diabetics or other patients with compromised immune systems or poor circulation of the lower extremities. VT-1161 has completed a Phase 2b trial in onychomycosis and met its primary endpoint of complete cure rates at 48 weeks.
PATRICK JORDAN, MA, MBA
Chief Executive Officer
STEPHEN BRAND, PhD
Senior Vice President, Clinical Development
THORSTEN DEGENHARDT, PhD
Senior Vice President, Global Operations
Senior Director, Project Management and Regulatory Affairs
KRISTEN OBERG, JD
Senior Director of Operations
CAROLINE CARR, CPA
Senior Director of Finance